SCHEMBL6403755

SCHEMBL6403755

CC(c1ccc(O)cc1)C(O)(O)c1c(O)cccc1P(=O)(O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.34
PDCD1 Q15116 1/20 0.34
ESR2 Q92731 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
PTPN2 P17706 1/20 0.32
PTPN1 P18031 1/20 0.32
PTPN5 P54829 1/20 0.32
KDM4E B2RXH2 2/20 0.31
MDM4 O15151 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
TYR P14679 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
ALOX12 P18054 1/20 0.31
CA5A P35218 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401986 0.88 ADRB1 (0.37) ESR1ESR2PTPN5KDM4EMDM4
SCHEMBL6396081 0.84 ESR1 (0.35) ESR1ESR2KDM4ECYP3A4MAPT
SCHEMBL6397899 0.83 ESR1 (0.34) ESR1PDCD1ESR2CD274KDM4E
SCHEMBL6397392 0.82 ESR1 (0.36) ESR1PDCD1ESR2CD274PTPN2
SCHEMBL6396330 0.80 INPPL1 (0.41) ESR1PDCD1ESR2CD274PTPN2
SCHEMBL6401894 0.80 ESR1 (0.32) ESR1PDCD1ESR2CD274PTPN2
SCHEMBL6404462 0.76 ADRB1 (0.39) ESR1ESR2PTPN5KDM4EMDM4
SCHEMBL6397135 0.75 FDPS (0.39) ESR1ESR2PTPN1CYP3A4
SCHEMBL7622352 0.75 ESR1 (0.46) ESR1PDCD1ESR2CD274PTPN2
SCHEMBL6401064 0.74 HDAC4 (0.35) ESR1ESR2KDM4EMDM4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885PDCD1 2817/4885ESR2 2416/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ESR1 3212/4885PDCD1 2853/4885ESR2 2699/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885PDCD1 2817/4885ESR2 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.